About: Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
Creator	Bjorkman, Pamela Michailidis, Eleftherios Nussenzweig, Michel Pak, John Rice, Charles Bieniasz, Paul Kost, Rhonda Agudelo, Marianna Ashbrook, Alison Barnes, Christopher Bianchini, Filippo Caskey, Marina Chen, Spencer Cho, Alice Cipolla, Melissa Dizon, Juan Finkin, Gaebler, Christian Gazumyan, Anna Gordon, Kristie Hagglof, Thomas Hartweger, Harald Hatziioannou, Theodora Hoffman, Pauline Hoffmann, Heinrich Horowitz, Jill Huey-Tubman, Kathryn Hurley, Arlene Koranda, Nicholas Lorenzi, Julio Mendoza, Pilar Millard, Katrina Muecksch, Frauke Nogueira, Lilian Oliveira, Thiago Pack, Maggi Patel, Roshni Ramos, Victor Robbiani, Davide Schmidt, Fabian Viant, Charlotte Waltari, Eric Weisblum, Yiska
Source	BioRxiv; Medline; PMC
abstract	During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2(1–5). Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC(50)s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1101/2020.05.13.092619
bibo:pmid	32511384
has license	cc-by-nc-nd
sha1sum (hex)	bdc93291835ac482e24ece71c9cb63e5418807e7
schema:url	https://doi.org/10.1101/2020.05.13.092619
resource representing a document's title	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
has PubMed Central identifier	PMC7263513
has PubMed identifier	32511384
schema:publication	bioRxiv
resource representing a document's body	covid:bdc93291835ac482e24ece71c9cb63e5418807e7#body_text
is schema:about of	named entity 'high' named entity 'rare' named entity 'clones' named entity 'RBD' named entity 'Thus' named entity 'spike' named entity 'vaccine' named entity 'symptoms' named entity 'However' named entity 'ranging' named entity 'vaccine' named entity 'Infection' named entity 'Antibody' named entity 'Responses' named entity 'Convergent' named entity 'cells' named entity 'individuals' named entity 'lives' named entity 'essential' named entity 'broadly' named entity 'variable' named entity 'hundreds' named entity 'epitopes' named entity 'During' named entity 'SARS-CoV-2' named entity 'binding domain' named entity 'Nevertheless' named entity 'half-maximal' named entity 'epitopes' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'plasma' named entity 'receptor binding domain' named entity 'COVID' named entity 'Antibody' named entity 'specific' named entity 'COVID-19' named entity 'p-values' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software